Fundraising FoxBiotechnology Value Fund — 2018 Investments
6 investments dated 2018 · listed companies and verified rows first · show all
Inventiva is a clinical-stage biopharmaceutical company developing drug candidates, with a focus on liver and other diseases.
BiotechMedical Devices
Co-investorsEuropean Investment BankAndera PartnersClaret Capital PartnersNew Enterprise Associates (NEA)Samsara BioCapitalSofinnova Partners+1 more
Lite Strategy, Inc.
BiotechCrypto & Web3FintechHealthtechSan Diego, US
David M. Urso(Executive Officer)inDaniel P. Gold(Executive Officer, Director)Brian G. Drazba(Executive Officer)inMr. File(Chief Executive Officer & Board Member (former CFO))Justin (Jay) File(CEO, CFO)inKevan E. Clemens(Director)
Co-investors3B Future Health FundAisling CapitalGSRNew Enterprise Associates (NEA)Primitive VenturesAmzak Health+1 more
Unity Biotechnology was a biotechnology company that is no longer operating.
BiotechBrisbane, US
Nathaniel E. David(Executive Officer, Director)inDan Marquess(Executive Officer)inKeith Leonard(Executive Officer, Director)inTamara Tompkins(Executive Officer)inBob Goeltz(Executive Officer)inJamie Dananberg(Executive Officer)in
Co-investorsage1Alumni VenturesARCH Venture PartnersCycad Group LLCEcoR1 CapitalKhosla Ventures+6 more
Ventus AI is an enterprise automation platform offering AI agents ("AI teammates") that operate inside existing systems—desktop apps, web portals, and legacy software—without API integrations to automate complex business workflows, handling MFA, CAPTCHAs, and phone calls.
AI & Machine LearningEnterprise SoftwareHealthtechCasa Grande, US
Maran Vedamanikam(CEO and Manager)Peter Qian(Co-founder & CEO)Vincent Lu(Co-founder & CTO)
Co-investorsSamsung NextAndreessen HorowitzWndrCoAlexandriaCasdin CapitalFonds de solidarité FTQ+5 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.